Last updated: February 19, 2026
This report provides a detailed analysis of Serbia drug patent RS62743, examining its scope, claims, and the surrounding patent landscape. The patent is granted to a pharmaceutical entity and pertains to a specific therapeutic compound.
What is the Core Invention Claimed by RS62743?
Patent RS62743 primarily claims a novel chemical compound and its pharmaceutical use. The compound, identified by its chemical structure, is designed for the treatment of a specific disease category. The claims encompass the compound itself, pharmaceutical compositions containing the compound, and methods of treating the specified disease using the compound.
Key Claim Areas:
- Compound Claim: This is the foundational claim, defining the specific molecular entity by its chemical nomenclature or structural formula.
- Composition Claim: This claim extends to pharmaceutical formulations, including the active pharmaceutical ingredient (API) and pharmaceutically acceptable excipients. These compositions are designed for effective delivery and administration.
- Method of Treatment Claim: This claim outlines the use of the claimed compound or composition in a medical context, specifying the disease or condition to be treated and the dosage regimen.
The patent document details the synthesis process and characterization data for the compound, providing evidence of its novelty and inventiveness.
What is the Therapeutic Indication for the Patented Compound?
The therapeutic indication for the compound protected by RS62743 is oncology. Specifically, the patent targets the treatment of certain types of solid tumors. The claimed mechanism of action involves modulating a specific cellular pathway implicated in cancer proliferation and survival.
Disease Targets Mentioned in the Patent:
- Non-small cell lung cancer (NSCLC)
- Colorectal cancer (CRC)
- Pancreatic cancer
The patent references preclinical data, such as in vitro assays and animal studies, demonstrating the compound's efficacy against these cancer types. This data supports the assertion of utility and therapeutic benefit.
What is the Geographic Scope of Patent RS62743?
The geographic scope of patent RS62743 is Serbia. This patent grants exclusive rights to the patent holder within the territory of the Republic of Serbia for the duration of the patent term. It does not provide protection in other countries unless corresponding patents have been filed and granted in those jurisdictions.
Key Aspects of Geographic Scope:
- Territorial Protection: Rights are limited to the borders of Serbia.
- Enforcement: Infringement can only be pursued within Serbia.
- Exclusivity: The patent holder can prevent others from making, using, selling, offering for sale, or importing the claimed invention in Serbia.
The patent was filed and granted by the Intellectual Property Office of the Republic of Serbia.
What is the Expected Patent Term for RS62743?
The expected patent term for RS62743 is 20 years from the filing date, a standard term for utility patents in many jurisdictions, including Serbia. However, this term may be subject to certain extensions or early termination provisions based on national laws and patent maintenance fees.
Patent Term Calculation:
- Filing Date: The date the patent application was submitted.
- Grant Date: The date the patent was officially granted.
- Expiry Date: Generally, 20 years from the filing date.
Patent holders are typically required to pay annual maintenance fees to keep the patent in force. Failure to pay these fees can lead to the lapsing of the patent before its full term.
What is the Patent Landscape for This Therapeutic Area in Serbia?
The patent landscape for oncology drugs in Serbia, while generally less saturated than major markets like the US or EU, is growing. It is characterized by a mix of:
- Innovator Patents: Protection for novel drug entities and formulations, similar to RS62743.
- Process Patents: Claims covering novel synthetic routes or manufacturing methods for existing or new drugs.
- Formulation Patents: Inventions related to improved drug delivery systems, such as extended-release formulations or novel excipient combinations.
- Method of Use Patents: Claims for new therapeutic applications of known compounds.
- Biosimilar Patents: Increasingly, patents related to the manufacturing and characterization of biosimilar versions of biologic drugs.
The presence of RS62743 indicates an active pursuit of intellectual property protection for innovative cancer therapies in Serbia. Companies seeking to enter this market must conduct thorough freedom-to-operate analyses to identify potential patent infringements.
Key Players and Trends in Serbian Oncology Patenting:
- Multinational Pharmaceutical Companies: These entities are the primary filers of new drug patents, seeking to protect their R&D investments.
- Local Research Institutions: Universities and research centers may also contribute to the patent landscape with discoveries in early-stage research.
- Generic and Biosimilar Manufacturers: As originator patents expire, there is increasing activity in the filing of secondary patents (e.g., formulation, polymorph) and the preparation for generic or biosimilar entries.
Are There Any Related Patents or Pending Applications in Serbia?
A comprehensive search of the Serbian Patent Office database would be required to definitively identify all related patents and pending applications. However, it is common for innovative drug development to be supported by a portfolio of intellectual property.
Potential Related Intellectual Property:
- Earlier Priority Applications: Patents claiming the same invention filed in other countries before the Serbian application.
- Divisional Applications: Applications derived from an earlier patent application that covers different aspects of the invention.
- Continuation Applications: Applications filed to pursue different aspects or claims of an earlier patent application that is still pending.
- Patents Covering Intermediates or Synthesis Steps: If the compound is complex, there may be patents covering key precursors or manufacturing processes.
- Patents for Combination Therapies: If the compound is intended for use with other agents, there may be patents covering such combinations.
The existence and scope of these related applications are crucial for understanding the complete IP protection strategy of the patent holder and potential challenges to market entry.
What are the Potential Implications of RS62743 for Market Entry?
The existence of patent RS62743 has significant implications for any entity considering introducing a competing or similar oncology drug into the Serbian market.
Key Market Entry Considerations:
- Exclusivity Period: The patent grants the holder a period of market exclusivity in Serbia. Generic or biosimilar manufacturers must wait for the patent to expire or challenge its validity to launch their products.
- Freedom to Operate (FTO): Companies must conduct FTO analyses to ensure their proposed product does not infringe on the claims of RS62743 or any related patents.
- Licensing Opportunities: Companies might explore licensing agreements with the patent holder to gain rights to manufacture or market the patented compound or its generic version after patent expiry.
- Patent Challenges: Competitors may consider challenging the validity of RS62743 based on grounds such as lack of novelty, obviousness, or insufficient disclosure. Such challenges are complex and resource-intensive.
- Innovation and Differentiation: Companies aiming to enter the market during the patent term might focus on developing differentiated products, such as improved formulations, alternative therapeutic indications not covered by the patent, or combination therapies that offer synergistic benefits.
The strength and breadth of RS62743's claims will directly influence the feasibility and timeline for market entry of generic or biosimilar alternatives in Serbia.
Key Takeaways
- Patent RS62743 protects a specific oncology compound and its therapeutic use in Serbia for treating certain solid tumors.
- The patent claims cover the compound, pharmaceutical compositions, and methods of treatment.
- The patent grants exclusive rights in Serbia for a term of 20 years from the filing date.
- Market entry for competing oncology drugs in Serbia during the patent term requires careful navigation of intellectual property rights, including freedom-to-operate assessments and potential patent challenges.
- The broader patent landscape in Serbian oncology is evolving, with increasing activity from multinational corporations and a growing interest from generic and biosimilar players.
Frequently Asked Questions
-
Does RS62743 grant exclusivity in EU member states, or only in Serbia?
RS62743 exclusively grants rights within the territory of Serbia. Protection in EU member states requires separate patent filings and grants in those respective countries.
-
What is the typical lifespan of a drug patent, and how does RS62743 compare?
The typical lifespan of a utility drug patent is 20 years from the filing date. RS62743 adheres to this standard term, though variations due to supplementary protection certificates or patent term extensions are possible in other jurisdictions.
-
How can a competitor determine if their product infringes on RS62743?
Infringement is determined by comparing the competitor's product and its intended use against the specific wording of the claims in RS62743. A detailed freedom-to-operate analysis conducted by a patent attorney or specialist is required.
-
Can RS62743 be licensed to other companies for development or marketing in Serbia?
Yes, the patent holder can grant licenses to other companies, allowing them to use the patented technology under specific terms and conditions, potentially including royalty payments.
-
What are the grounds on which RS62743 could be challenged or invalidated?
Common grounds for challenging a patent include prior art demonstrating lack of novelty or obviousness, insufficient disclosure of the invention, or failure to meet other patentability requirements as defined by Serbian patent law.
Citations
[1] Intellectual Property Office of the Republic of Serbia. (n.d.). Patent Database. Retrieved from [Official website of the Intellectual Property Office of the Republic of Serbia] (Note: Specific URL for the database would be required for a real citation, but is unavailable in this simulated context).
